Dermatomyositis sine dermatitis-an unusual non classical dermatomyositis with amyopathic myopathy tale: a case report
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20252139Keywords:
Dermatomyositis sine dermatitis, Juvenile dermatomyositis, Anti-NXP2 antibody, Amyopathic dermatomyositis, HypokalemiaAbstract
We report a 13-year-old girl with dermatomyositis sine dermatitis (DMSD), a rare form of juvenile DM characterized by muscle weakness without skin rash. She presented with 2 months of progressive proximal limb weakness, neck weakness, and bilateral hand paresthesias, but no skin findings. Laboratory tests showed elevated inflammation with normal creatine kinase and significant hypokalemia. Myositis autoantibody testing revealed strongly positive anti-NXP2 and anti-Ku antibodies. A diagnosis of DMSD was made. High-dose corticosteroids plus supportive care and physiotherapy led to rapid recovery. This case highlights that DM should be considered even without rash. Anti-NXP2 positivity, associated with the sine-dermatitis phenotype, aided in confirming the diagnosis. Early recognition and treatment were crucial to the good outcome.
Metrics
References
Park JS, Park JY. Dermatomyositis sine dermatitis, a rare phenotype of idiopathic inflammatory myopathy. J Yeungnam Med Sci. 2017;34(1):137-9. DOI: https://doi.org/10.12701/yujm.2017.34.1.137
Patil A, Lu J, Kassir M, Babaei M, Goldust M. Adult and juvenile dermatomyositis treatment. J Cosmet Dermatol. 2023;22(2):395-401. DOI: https://doi.org/10.1111/jocd.15363
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96-100.
Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100(1):124-7. DOI: https://doi.org/10.1111/1523-1747.ep12356896
Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283-96. DOI: https://doi.org/10.1016/j.jaad.2019.05.105
Inoue M, Tanboon J, Hirakawa S, Komaki H, Fukushima T, Awano H, et al. Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurol. 2020;77(7):872-7. DOI: https://doi.org/10.1001/jamaneurol.2020.0673
Butt Z, Patel L, Das MK, Mecoli CA, Ramji A. NXP‐2 positive dermatomyositis: a unique clinical presentation. Case Rep Rheumatol. 2017;2017:4817275. DOI: https://doi.org/10.1155/2017/4817275
Ramesh HM, Gude SS, Venugopal S, Peddi NC, Vuppalapati S, Gude SS. The role of myositis-specific autoantibodies in the dermatomyositis spectrum. Cureus. 2022;14(3):e22978.
Madurapperuma MC, Poobalasingam T, Constantine S, De Silva M, Karunatilake H. An unusual presentation of dermatomyositis: dermatomyositis sine dermatitis presenting with rapidly progressive myositis. Asian J Intern Med. 2024;3(2):108-12. DOI: https://doi.org/10.4038/ajim.v3i2.170
Vahora I, Lingireddy A, Nadella S, Trivedi B, Dihowm F. A case report on rare presentation of sporadic disease: Dermatomyositis sine dermatitis-diagnosis and management. J Investig Med High Impact Case Rep. 2022;10:23247096221121403. DOI: https://doi.org/10.1177/23247096221121403
Khan N, Kazmi ZH, Alkhateb R. A rare case of NXP-2 positive dermatomyositis. Arch Clin Cases. 2021;7(4):68. DOI: https://doi.org/10.22551/2020.29.0704.10176
Ali O. A case report of severe idiopathic dermatomyositis with NXP-2 positive antibody. Open J Clin Med Case Rep. 2018;4(17):1-4.
Blah GR, Indu MB, Sharma B, Saran RK, Chawla R. An atypical presentation of dermatomyositis sine dermatitis. Ann Rheumatol Autoimmun. 2023;3(1):11-3. DOI: https://doi.org/10.4103/ara.ara_15_22
Pokhrel S, Pardhe BD, Giri N, Pokhrel R, Paudel D. Classical dermatomyositis: a case report. Clin Cosmet Investing Dermatol. 2020;13:123-6. DOI: https://doi.org/10.2147/CCID.S234452
Smith HG. Dermatomyositis. Br Med J. 1955;1(4916):770. DOI: https://doi.org/10.1136/bmj.1.4916.770
Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24(6):959-66. DOI: https://doi.org/10.1016/0190-9622(91)70153-S
Fujimoto M. Dermatomyositis: myositis‐specific autoantibodies and skin manifestations. Clin Exp Neuroimmunol. 2012;3(2):74-84. DOI: https://doi.org/10.1111/j.1759-1961.2012.00028.x
Rider LG, Werth VP, Huber AM, Giannini EH, Higgins GC, Lindsley CB, et al. Measures of juvenile dermatomyositis: the Childhood Myositis Assessment Scale (CMAS). Arthritis Rheum. 2010;62(10):3036-43.
Rider LG, Aggarwal R, Pinal-Fernandez I, Oddis CV, Giannini EH, Fertig N, et al. 2017 American College of Rheumatology/European League Against Rheumatism classification criteria for adult idiopathic inflammatory myopathies. Arthritis Rheumatol. 2017;69(12):2565-75.
Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971-82. DOI: https://doi.org/10.1016/S0140-6736(03)14368-1
Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine SM. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591-601. DOI: https://doi.org/10.1084/jem.20041367
Fiorentino D, Chung LS, Christopher-Stine L, Zaba L, Li S, Casciola-Rosen L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954-62. DOI: https://doi.org/10.1002/art.38093
Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-aminoacyl tRNA synthetase antibody in patients with interstitial lung disease. Autoimmunity. 2005;38(1):57-60.
Targoff IN. Autoantibodies in the myositis syndromes. Curr Rheumatol Rep. 2000;2(3):201-7.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96-100. DOI: https://doi.org/10.1016/S0140-6736(00)03540-6